Skip to main content

Wegovy and Pregnancy: Everything You Need to Know

If you\'re taking Wegovy and planning to become pregnant, understanding semaglutide\'s safety profile and the recommended washout period is essential for safe conception and pregnancy outcomes.

Semaglutide Pregnancy Category and FDA Classification

Semaglutide (the active ingredient in Wegovy) was historically classified as FDA Pregnancy Category C, indicating that animal reproduction studies have shown adverse effects, but no adequate human studies exist. However, the FDA discontinued the letter category system in 2016, replacing it with narrative labeling that provides more detailed information about pregnancy and lactation risks.

The current FDA label for semaglutide states that it\'s not recommended during pregnancy. This recommendation is based on limited human pregnancy data and animal study findings, not proven human harm at therapeutic doses. Most obstetricians treat semaglutide as a medication to discontinue before conception rather than an absolute teratogen.

Recommended Washout Period Before Conception

Manufacturers recommend a washout period of approximately 2 months (8 weeks) before attempting conception. This timeline accounts for the pharmacokinetics of semaglutide and allows the medication to be substantially eliminated from your body.

Semaglutide has a relatively short half-life of about 7 days, meaning half the drug is eliminated every week. After 2 months, more than 99% of the medication will have cleared from your system. This conservative 8-week window provides additional safety margin and aligns with current clinical practice guidelines.

The timing is straightforward: if you\'re planning to conceive in the next few months, discuss stopping Wegovy with your healthcare provider now. This allows time for the washout period while you prepare other aspects of pregnancy planning, such as prenatal vitamins and fertility optimization.

What Animal Studies Show About Semaglutide and Pregnancy

Preclinical (animal) studies of semaglutide in pregnant rats and rabbits were conducted at doses substantially higher than the recommended human dose of 2.4 mg weekly. These studies did not demonstrate teratogenic effects (birth defects) at the highest doses tested, which is reassuring.

However, animal studies have shown that semaglutide can affect glucose homeostasis and maternal weight in pregnant animals. This raised theoretical concerns about metabolic effects during human pregnancy, particularly in the context of gestational diabetes risk and maternal metabolic changes.

It\'s important to note that animal studies don\'t always predict human outcomes. The absence of birth defects in animals at high doses is reassuring, but the limited human pregnancy data means uncertainty remains. This is why the conservative approach of washout before conception is recommended rather than continuation during pregnancy.

Accidental Exposure During Early Pregnancy

If you became pregnant while taking Wegovy—perhaps before realizing you were pregnant—this doesn\'t automatically indicate harm to the pregnancy. Accidental first-trimester semaglutide exposure has been reported in case reports and patient registries without clear evidence of increased birth defect risk.

What you should do if this occurs:

  • Contact your obstetrician immediately to inform them of the exposure
  • Provide information about the dose, frequency, and timing of Wegovy use
  • Discuss options for enhanced prenatal monitoring if your OB/GYN recommends it
  • Ask about referral to maternal-fetal medicine if your obstetrician suggests specialist evaluation
  • Keep detailed records of when you stopped Wegovy and what the pregnancy timeline shows

Many obstetricians take a reassuring approach to accidental first-trimester semaglutide exposure, especially given the negative animal teratogenicity data. However, individual management depends on your specific circumstances and your provider\'s assessment.

Semaglutide and Breastfeeding

Data on semaglutide excretion into breast milk is extremely limited. The drug is a large peptide (31 amino acids), which typically aren\'t absorbed intact from the gastrointestinal tract, but this doesn\'t guarantee safety in breastfed infants.

Most lactation specialists and pediatricians currently recommend avoiding semaglutide during breastfeeding until more data becomes available. The standard recommendation is to discontinue Wegovy for the duration of breastfeeding and resume after weaning is complete.

If you\'ve delivered a baby and want to resume Wegovy while considering breastfeeding, discuss this with both your obstetrician and pediatrician. Some healthcare providers may accept the risk based on individual circumstances, while others maintain the conservative "avoid during lactation" approach.

For more detailed information on this topic, see our guide on semaglutide and breastfeeding.

Effects on Fertility and Ovulation

Semaglutide itself doesn\'t directly suppress ovulation or impair fertility at the cellular level. However, its effects on appetite and weight loss can indirectly affect reproductive function in several ways.

For people with weight-related anovulation (irregular or absent ovulation due to excess weight), Wegovy-induced weight loss can actually restore ovulatory cycles and improve fertility. This is a positive effect for those seeking to conceive.

However, some Wegovy users report changes in menstrual regularity during treatment—either becoming more regular or experiencing temporary disruption. These changes are typically related to the rapid weight loss rather than semaglutide\'s direct hormonal effects. Most menstrual irregularities resolve after initial weight loss stabilizes.

If you\'re experiencing concerning changes in your menstrual cycle while on Wegovy, discuss this with your healthcare provider. They can assess whether the changes are expected or warrant investigation.

Pregnancy Planning While on Wegovy

If you\'re planning to become pregnant within the next few months, your healthcare provider may recommend one of several strategies:

Strategy 1: Stop Wegovy now, wait 2 months, then attempt conception. This is the most conservative approach and aligns with manufacturer recommendations. You\'ll use the 2-month washout period to optimize prenatal health (prenatal vitamins, folic acid, general health screening).

Strategy 2: Continue Wegovy while optimizing other conception factors. Some fertility specialists might support continuing Wegovy during the fertility-tracking phase if you\'re not yet conceived, then stopping once a positive pregnancy test occurs. This requires careful planning and communication with your OB/GYN.

Strategy 3: Switch to alternative weight management. If maintaining weight loss is important for your conception planning, your provider might recommend transitioning to non-pharmacologic approaches (diet, exercise, behavioral support) instead of Wegovy, so no washout period is needed.

Discuss these options with your obstetrician well in advance of when you\'re ready to attempt conception. This allows time for planning and prevents rushing the decision.

Related Guides and Resources

For more information on semaglutide and reproductive health, explore these related guides:

Frequently Asked Questions

The recommended washout period is 2 months (8 weeks) before attempting conception. This allows semaglutide to clear from your system, though it's quickly eliminated with a half-life of 7 days.

Accidental exposure to semaglutide in early pregnancy doesn't automatically indicate harm, but you should immediately inform your obstetrician. Animal studies didn't show teratogenic effects at recommended doses, but human pregnancy data remains limited.

Semaglutide is FDA Pregnancy Category C (prior labeling), though the FDA moved away from letter categories in 2016. Current guidance treats it as requiring caution in pregnancy due to limited human data, not absolute contraindication.

Data on semaglutide in breast milk is extremely limited. Most experts recommend discontinuing Wegovy during breastfeeding and waiting until weaning is complete before resuming. Consult your pediatrician about individual risk-benefit.

Semaglutide itself doesn't directly impair ovulation, but weight loss from Wegovy can restore regular ovulation in people with weight-related anovulation. However, some users report changes in menstrual regularity during treatment.

Yes, absolutely. Your OB/GYN can review your medical history, help establish the 2-month washout timeline, and monitor any metabolic changes. They can also discuss alternative weight management strategies if needed during pregnancy.